secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001193125-22-146410
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Coherus Biosciences appoints Charles Newton to Board of Directors
-----------------------------------------------------------------

- Charles Newton appointed as Class I director effective May 4, 2022, term expiring at 2024 annual meeting.
- Newton also appointed to audit committee; is CFO of Lyell Immunopharma, a Nasdaq-listed biotech.
- He receives $50,000 annual cash retainer and option to purchase 54,000 shares vesting over 3 years.
- Newton previously co-headed healthcare investment banking at BofA Securities and Credit Suisse.
- No material transactions requiring disclosure under Item 404(a) identified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000119312522146410/0001193125-22-146410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000119312522146410/d328049d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-146410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer